TY  - GEN
AU  - Liu,Joyce F
AU  - Tolaney,Sara M
AU  - Birrer,Michael
AU  - Fleming,Gini F
AU  - Buss,Mary K
AU  - Dahlberg,Suzanne E
AU  - Lee,Hang
AU  - Whalen,Christin
AU  - Tyburski,Karin
AU  - Winer,Eric
AU  - Ivy,Percy
AU  - Matulonis,Ursula A
TI  - A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
SN  - 1879-0852
PY  - 2013///1113
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Capsules
KW  - Carcinoma, Ovarian Epithelial
KW  - Diarrhea
KW  - chemically induced
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Fatigue
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Nausea
KW  - Neoplasm Recurrence, Local
KW  - Neoplasms, Glandular and Epithelial
KW  - Ovarian Neoplasms
KW  - Phthalazines
KW  - administration & dosage
KW  - Piperazines
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Quinazolines
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - antagonists & inhibitors
KW  - Tablets
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1016/j.ejca.2013.05.020
ER  -